Targeting GLUT1 to Control Autoimmunity in Type 1 Diabetes

Sponsor
IRCCS San Raffaele
Study ID
NCT07695727
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Type 1 Diabetes is an autoimmune disease in which immune cells contribute to the destruction of insulin-producing pancreatic beta cells. This study investigates whether targeting glucose transporter 1 (GLUT1), a transporter involved in immune cell metabolism, may help modulate autoimmune responses associated with Type 1 Diabetes. The study uses previously collected and biobanked peripheral blood mononuclear cells (PBMCs) from individuals with Type 1 Diabetes. No additional visits, blood draws, or study-specific procedures will be performed on human participants.

Key Dates

First listed
Jul 10, 2026
Start date
Sep 30, 2026
Status verified
Jul 2026
Primary completion
Sep 30, 2029
Completion
Sep 30, 2029

Study Design

Enrollment
84 participants (estimated)

Arms

  • Arm: Adults With Type 1 Diabetes
    Previously collected PBMC samples obtained from adult subjects with a documented diagnosis of Type 1 Diabetes and stored at the institutional Biobank of IRCCS Ospedale San Raffaele.

Primary Outcome Measure

Human Immune Cell Engraftment/Reconstitution [ Time Frame: 28 days after peripheral blood mononuclear cells (PBMCs) infusion ]

Central Contacts

Find similar trials

Nationwide
Type 1 diabetes trialsEndocrinology trials

Related Studies